Spatiotemporal Dysfunction of the Vascular Permeability Barrier in Transgenic Mice with Sickle Cell Disease

Samit Ghosh, Emory University
Fang Tan, Emory University
Solomon F. Ofori-Acquah, Emory University

Journal Title: Anemia
Volume: Volume 2012
Publisher: Hindawi Publishing Corporation | 2012-02-15, Pages 1-6
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1155/2012/582018
Permanent URL: http://pid.emory.edu/ark:/25593/cw2tp

Final published version: http://dx.doi.org/10.1155%2F2012%2F582018

Copyright information:
© 2012 Samit Ghosh et al.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/).

Accessed November 12, 2022 7:31 PM EST
Spatiotemporal Dysfunction of the Vascular Permeability Barrier in Transgenic Mice with Sickle Cell Disease

Samit Ghosh, Fang Tan, and Solomon F. Ofori-Acquah

1 Aflac Cancer and Blood Disorders Center, Division of Hematology/Oncology/BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA
2 Department of Pediatrics, Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA

Correspondence should be addressed to Solomon F. Ofori-Acquah, soforia@emory.edu

Received 16 December 2011; Accepted 15 February 2012

Academic Editor: Kenneth R. Peterson

Sickle cell disease (SCD) is characterized by chronic intravascular hemolysis that generates excess cell-free hemoglobin in the blood circulation. Hemoglobin causes multiple endothelial dysfunctions including increased vascular permeability, impaired reactivity to vasoactive agonists, and increased adhesion of leukocytes to the endothelium. While the adhesive and vasomotor defects of SCD associated with cell-free hemoglobin are well defined, the vascular permeability phenotype remains poorly appreciated. We addressed this issue in two widely used and clinically relevant mouse models of SCD. We discovered that the endothelial barrier is normal in most organs in the young but deteriorates with aging particularly in the lung. Indeed, middle-aged sickle mice developed pulmonary edema revealing for the first time similarities in the chronic permeability phenotypes of the lung in mice and humans with SCD. Intravenous administration of lysed red blood cells into the circulation of sickle mice increased vascular permeability significantly in the lung without impacting permeability in other organs. Thus, increased vascular permeability is an endothelial dysfunction of SCD with the barrier in the lung likely the most vulnerable to acute inflammation.

1. Introduction

Sickle cell disease (SCD) is characterized by the production of red blood cells with increased propensity for lysis and adhesion [1]. Its clinical manifestations fall broadly into two subphenotypes defined by hyperhemolysis and vasoocclusion [2]. At least 30% of the hemolysis in SCD is intravascular [3], which means that the endothelial wall in this disease is persistently exposed to cell-free hemoglobin. The endothelium is a semipermeable barrier that regulates the response of the vascular wall to inflammatory agonists. This response involves activation of adhesion molecule expression, increased permeability of the endothelium, and extravasation of fluid from the blood into interstitial tissue compartments [4]. Increased vascular permeability results from opening of gaps at sites of endothelial cell-cell contacts. There are multiple indicators of systemic inflammation in SCD [5]. In addition, markers of vascular inflammation have also been documented [6–8]. There is increased expression of adhesion molecules in the pulmonary endothelium of the Berkeley sickle mice [9], although the histology of these same mice shows less severe inflammatory and ischemic changes and no evidence of pneumonia [10]. Nonetheless, they spontaneously develop pulmonary hypertension [11], which is a major problem in SCD [12]. Pulmonary edema and the acute chest syndrome implicate increased vascular permeability in both chronic and acute complications of SCD [13, 14]. Despite this significance, there is currently no knowledge of the vascular permeability phenotypes of major organs that are impacted by SCD.

2. Materials and Methods

2.1. Transgenic Sickle Mice. Experiments were performed using protocols approved by the Institutional Animal Care and Use Committee (IACUC) of Emory University. The Berkeley [15] and Townes [16] transgenic SCD mouse models used have previously been described.
Figure 1: Continued.
2.2. Vascular Leakage and Lung Edema. Vascular leakage was studied by intravenous injection of cell-impermeable Evan’s Blue dye as widely described by several investigators. Mice were injected with 100 μL of 1% cell-impermeable Evans Blue dye (Sigma-Aldrich, St. Louis, MO) in PBS intravenously through tail vein. After 40 min, mice were anesthetized by i.p. injection of avertin (300 mg/kg body weight). To remove the dye from circulation, mice were perfused by injecting 40 mL of PBS containing 2 mM EDTA through left ventricle of the heart allowing the blood to flow out by puncturing renal artery. Organs were harvested and incubated in formamide for 3 days to extract the dye and OD determined at 620 nm. For edema analysis mice were euthanized and the right lobe removed and weighed immediately using an isometric...
transducer (Harvard Apparatus, Holliston, MA). Lungs were dried in an oven at 80°C containing desiccant crystals for 24 h, dry weight determined, and ratios calculated.

2.3. Statistical Analyses. GraphPad software version 5.0 was used. Differences in vascular leakage and weights were analyzed using t-test and correlation studies performed using Pearson’s test.

3. Results and Discussion

In SCD, the adhesive and vasomotor defects of the vasculature are well defined [17–20], while the vascular permeability remains poorly appreciated. To address this knowledge gap, adult (3–6 months) and middle-aged (10–13 months) mice were injected with 1% Evans blue via the tail vein and the amount of dye that leaked from the circulation into the parenchyma of individual organs examined. Figure 1(a) shows virtually no leakage in the brain contrary to the clear evidence of endothelial barrier breakdown in the other organs. Quantification of vascular leakage revealed that the endothelial barrier is generally more permeable in the sickle mice than in control littermates (Figures 1(b) and 1(c)), despite some differences in the two transgenic models. Indeed, there was a significant correlation between steady-state hemoglobin concentration and lung permeability (Figure 1(d)) \((r = -0.7639, P < 0.0001)\), indicating that endothelial barrier dysfunction is related to an aspect of SCD. Unlike most organs, vascular permeability in the lung in middle-aged sickle mice was significantly higher than in adult mice, highlighting a role for age in this disease process. This was investigated by extending our study to include younger mice aged 5–6 weeks. Remarkably, permeability in the heart and lung at this early stage of the disease was identical to that of the brain, which is widely known to have a highly restrictive barrier (Figures 1(e) and 1(f)). Thus, the endothelial barrier in SCD is normal in most organs in the young, becomes abnormal during adulthood, and deteriorates further with aging particularly in the lung.

Pulmonary edema is a common postmortem finding in SCD and yet it has not been appreciated as a chronic lung complication of SCD, probably because of the confounding effect of death [21, 22]. While histology does not reveal evidence of edema in the Berkeley sickle mice [10], we have used a more sensitive approach to clearly demonstrate that vascular permeability in the lungs of both the Berkeley and Townes sickle mice is increased. Our result is in agreement with a recent study that investigated permeability exclusively in the lung of 12–16-weeks-old NY1DD sickle mouse using the same approach [23]. In agreement with these permeability findings, we discovered that the average wet lung weight of middle-aged sickle mice is significantly heavier than that of age-matched hemizygotes \((0.64 \text{ mg} \pm 0.04 \text{ versus } 0.54 \text{ mg} \pm 0.02; P = 0.03)\), and, accordingly, the wet/dry weight ratio, widely used to confirm edema in lungs, was significantly higher \((P = 0.002)\) (Figure 2(a)). Taken together, these results show for the first time that middle-aged sickle mice develop pulmonary edema. We cannot exclude the possibility that chronic heart failure contributed to the lung edema reported here; however, the Berkeley mice used in the lung weight measurements were at least three months younger than those reported to have heart failure [11]. Importantly, we show that lung edema correlates with higher vascular permeability in sickle mouse lungs. This concordance advances both conceptual and practical research objectives. It suggests
that the permeability phenotypes of the lung in mice and humans with SCD are similar, and it validates, for the first time, the use of the Evans blue extravasation approach to study vascular permeability in transgenic sickle mice.

The permeability phenotypes identified here likely reflect the intrinsic properties of individual organs, as well as of endothelial cell types. For instance, it is well established that heterogeneity of endothelial cell junction contributes to unique permeability attributes [24], and this may account for some of the dramatic differences in permeability phenotypes reported here (e.g., brain and lung). However, endothelial cells in individual organs may also respond differently to barrier disrupting factors found in SCD. Among these factors, cell-free hemoglobin is unique because it is released in abundance during acute intravascular hemolysis, which is a daily event in SCD. We assessed the response of major vascular beds in the sickle mice to acute hemolysis. Leuko-depleted packed red blood cells were lysed by repeated freeze-thaw cycles and intravenously administered to sickle mice via tail vein. Compared to saline, the lysed red blood cells increased vascular permeability by 2-fold in the lungs of adult sickle mice but had a modest or negligible impact on the kidney, brain, and heart (Figure 2(b)). That lysed red blood cells caused morbidity and significantly altered barrier function in the Berkeley sickle mice indicates this and other severe models of SCD can be used to unlock mechanisms of acute hemolysis in SCD. In particular the vulnerability of the lung endothelial barrier to lysed red blood cells highlights acute intravascular hemolysis as a potential trigger of the acute chest syndrome since a decreasing concentration of hemoglobin is invariably associated with this condition [14].

In conclusion, SCD appears to be characterized by weakening of the endothelial barrier, which predisposes some organs, such as the lung to acute loss of barrier function, reminiscent of the acute chest syndrome. Ongoing studies are focused on unraveling the relationship between acute hemolysis and the endothelial barrier in SCD.

Authors’ Contribution

S. Ghosh designed and performed most of the experiments. F. Tan characterized the transgenic mice and performed research. S. F. Ofori-Acquah designed the study and provided overall oversight of the projects.

Acknowledgments

The authors are grateful to Dr. Townes of the University of Alabama at Birmingham for the knock-in transgenic mice with SCD and to Dr. Archer of Emory University for the Berkeley mice. This work was supported by Grants R01HL077769 awarded to SFOA.

References

[1] S. Embury, R. P. Hebbel, N. Mohandas, and M. H. Steinberg, Sickle Cell Disease: Basic Principles and Clinical Practice, Raven Press, New York, NY, USA, 1995.
[2] G. J. Kato, M. T. Gladwin, and M. H. Steinberg, “Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes,” Blood Reviews, vol. 21, no. 1, pp. 37–47, 2007.
[3] T. A. Bensinger and P. N. Gillette, “Hemolysis in sickle cell disease,” Archives of Internal Medicine, vol. 133, no. 4, pp. 624–631, 1974.
[4] W. Aird, Endothelial Biomedicine, Cambridge University Press, 2007.
[5] M. H. Steinberg, “Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches,” TheScientificWorldJournal, vol. 8, pp. 1295–1324, 2008.
[6] A. J. Duits, R. C. Pieters, A. W. Saleh et al., “Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis,” Clinical Immunology and Immunopathology, vol. 81, no. 1, pp. 96–98, 1996.
[7] A. Solovey, Y. Lin, P. Browne, S. Choong, E. Wayner, and R. P. Hebbel, “Circulating activated endothelial cells in sickle cell anemia,” New England Journal of Medicine, vol. 337, no. 22, pp. 1584–1590, 1997.
[8] A. Solovey, L. Gui, N. S. Key, and R. P. Hebbel, “‘Tissue factor expression by endothelial cells in sickle cell anemia,” Journal of Clinical Investigation, vol. 101, no. 9, pp. 1899–1904, 1998.
[9] J. D. Belcher, C. J. Bryant, J. Nguyen et al., “Transgenic sickle mice have vascular inflammation,” Blood, vol. 101, no. 10, pp. 3953–3959, 2003.
[10] E. A. Manci, C. A. Hillery, C. A. Bodian, Z. G. Zhang, G. A. Lutty, and B. S. Coller, “Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease,” Blood, vol. 107, no. 4, pp. 1651–1658, 2006.
[11] L. L. Hsu, H. C. Champion, S. A. Campbell-Lee et al., “Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability,” Blood, vol. 109, no. 7, pp. 3088–3098, 2007.
[12] M. T. Gladwin, V. Sachdev, M. L. Jison et al., “Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease,” New England Journal of Medicine, vol. 350, no. 9, pp. 886–895, 2004.
[13] J. K. Graham, M. Mosunjac, R. L. Hanzlick, and M. Mosunjac, “Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review,” American Journal of Forensic Medicine and Pathology, vol. 28, no. 2, pp. 168–172, 2007.
[14] E. P. Vichinsky, L. D. Neumayr, A. N. Earles et al., “Causes and outcomes of the acute chest syndrome in sickle cell disease,” New England Journal of Medicine, vol. 342, no. 25, pp. 1855–1865, 2000.
[15] C. Pászty, C. M. Brion, E. Manci et al., “Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease,” Science, vol. 278, no. 5339, pp. 876–878, 1997.
[16] L. C. Wu, C. W. Sun, T. M. Ryan, K. M. Pawlik, J. Ren, and T. M. Townes, “Correction of sickle cell disease by homologous recombination in embryonic stem cells,” Blood, vol. 108, no. 4, pp. 1183–1188, 2006.
[17] C. D. Reiter, X. Wang, J. E. Tanus-Santos et al., “Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease,” Nature Medicine, vol. 6, no. 12, pp. 1383–1389, 2002.
[18] M. T. Gladwin, V. Sachdev, M. L. Jison et al., “Pulmonary hypertension as a risk factor for death in patients with sickle cell disease,” New England Journal of Medicine, vol. 350, no. 9, pp. 886–895, 2004.
[19] R. P. Hebbel, R. Osarogiagbon, and D. Kaul, “The endothelial biology of sickle cell disease: inflammation and a chronic
vasculopathy,” *Microcirculation*, vol. 11, no. 2, pp. 129–151, 2004.

[20] B. N. Y. Setty and M. J. Stuart, “Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease,” *Blood*, vol. 88, no. 6, pp. 2311–2320, 1996.

[21] J. K. Graham, M. Mosunjac, R. L. Hanzlick, and M. Mosunjac, “Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review,” *American Journal of Forensic Medicine and Pathology*, vol. 28, no. 2, pp. 168–172, 2007.

[22] W. Girard, “Case report: postoperative pulmonary edema and sickle cell crisis,” *Clinical Notes on Respiratory Diseases*, vol. 17, no. 4, pp. 13–14, 1979.

[23] K. L. Wallace, M. A. Marshall, S. I. Ramos et al., “NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-γ and CXCR3 chemokines,” *Blood*, vol. 114, no. 3, pp. 667–676, 2009.

[24] A. Masedunskas, J. A. King, F. Tan et al., “Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration,” *FEBS Letters*, vol. 580, no. 11, pp. 2637–2645, 2006.
